Navidea Biopharma (NAVB) Reports Q4 Loss of $0.03

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.03), versus ($0.02) reported last year. Revenue for the quarter came in at $395 thousand, versus $1 million reported last year.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)